Hims Expands into Hormone Care and At-Home Testing Services
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HIMS?
Source: stocktwits
- Hormone Care Expansion: Hims recently launched Testosterone Rx+, a once-daily pill that combines Enclomiphene with zinc, vitamins B6, B12, and L-arginine, with 95% of users seeing increased testosterone levels within two months, highlighting the company's growth potential in hormone health.
- FDA Review Drives New Revenue: Bank of America Securities indicated that Hims' stock could rise due to upcoming FDA reviews of several peptide substances, which may open new revenue streams and allow the company to repurpose its existing GLP-1 infrastructure.
- Branded Drug Strategy: Hims' partnerships with Novo Nordisk and Eli Lilly signify a shift towards branded drugs, with expectations to exceed a run rate of over 100,000 Wegovy prescriptions per month, showcasing the company's competitive positioning in the market.
- Market Sentiment Shift: Despite Hims' shares rising over 1% on Monday, retail investor sentiment has shifted from 'bullish' to 'bearish', reflecting concerns about the company's future performance, with a 24% decline in stock price over the past year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 27.170
Low
16.50
Averages
32.95
High
60.00
Current: 27.170
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims Expands into Hormone Care and At-Home Testing Services
- Hormone Care Expansion: Hims recently launched Testosterone Rx+, a once-daily pill that combines Enclomiphene with zinc, vitamins B6, B12, and L-arginine, with 95% of users seeing increased testosterone levels within two months, highlighting the company's growth potential in hormone health.
- FDA Review Drives New Revenue: Bank of America Securities indicated that Hims' stock could rise due to upcoming FDA reviews of several peptide substances, which may open new revenue streams and allow the company to repurpose its existing GLP-1 infrastructure.
- Branded Drug Strategy: Hims' partnerships with Novo Nordisk and Eli Lilly signify a shift towards branded drugs, with expectations to exceed a run rate of over 100,000 Wegovy prescriptions per month, showcasing the company's competitive positioning in the market.
- Market Sentiment Shift: Despite Hims' shares rising over 1% on Monday, retail investor sentiment has shifted from 'bullish' to 'bearish', reflecting concerns about the company's future performance, with a 24% decline in stock price over the past year.
See More
Analysis of Investment Opportunities and Risks in Small-Cap Stocks
- Herbalife Performance Warning: With a market cap of $1.72 billion, Herbalife's organic sales have shown weakness over the past two years, and projected growth of only 4.3% over the next 12 months may force the company to make strategic adjustments or rely on M&A for faster growth.
- Jackson Financial Earnings Pressure: Jackson Financial, valued at $8.15 billion, has seen net premiums earned grow by just 1.9% annually over the last two years, while rising day-to-day expenses have led to a 32.8 percentage point drop in pre-tax profit margins, creating headwinds for future returns.
- Hims & Hers Health Optimistic Outlook: Hims & Hers Health, with a market cap of $6.19 billion, has averaged a 29.5% customer growth rate over the past two years, indicating strong capabilities in securing and expanding contracts, which could lead to significant sales growth.
- Market Volatility and Investment Strategy: Small-cap stocks like those in the Russell 2000 offer opportunities to uncover hidden gems, but their higher volatility and risk necessitate careful selection by investors, particularly during economic downturns.
See More
Hims Launches Testosterone Rx+ to Boost Hormone Therapy Offerings
- New Drug Launch: Hims has introduced Testosterone Rx+, a once-daily pill designed to help men naturally increase testosterone levels, marking a significant expansion in the company's hormone therapy offerings and potentially creating a new growth pillar.
- FDA Support: The rollout follows the FDA's encouragement for sponsors of approved testosterone replacement therapies to explore new indications for treating low libido, which could significantly boost market demand for testosterone therapies.
- Positive Customer Feedback: Company data indicates that 95% of customers experienced increases in testosterone levels, with 80% reaching optimal levels within 60 days, demonstrating the product's strong market appeal and effectiveness.
- Intensifying Market Competition: Amid tightening regulations on GLP-1 drugs, Hims' expansion into testosterone therapy is crucial for generating additional revenue streams, helping the company maintain competitiveness in the increasingly crowded weight-loss treatment market.
See More
FDA Proposes Exclusion of Weight Loss Drug Ingredients
- FDA Proposal: The U.S. Food and Drug Administration (FDA) has proposed to exclude Semaglutide and Tirzepatide from the 503B bulk list, limiting the compounding capabilities of outsourcing facilities, which may impact the market supply and accessibility of these drugs.
- Insufficient Clinical Need: The FDA stated that after reviewing available data, it found no clear clinical need to allow compounding of these drugs from raw ingredients, emphasizing patient safety and medical necessity, which could lead to restrictions on the use of related medications.
- Quality and Safety Concerns: The FDA has expressed concerns regarding the quality and safety of compounded weight-loss drugs, noting that these drugs are not reviewed by the FDA, which may pose risks such as improper storage, dosing errors, and counterfeit products, thereby affecting patient health.
- Market Reaction: Following the FDA proposal, shares of Eli Lilly and Novo Nordisk rose by 9% and 5%, respectively, indicating increased market confidence in the FDA-approved drugs from these companies, while Hims & Hers and Teladoc Health saw slight declines, reflecting market concerns over compounded medications.
See More
FalconX-Linked Address Adds 11.94 Million USDT to HyperLiquid, Boosting Crude Oil Long Position to 202,000 CL Tokens.
Investment in HyperLiquid: A wallet associated with Falcon X has deposited 11.94 million USDC into HyperLiquid, increasing its CL20x long position to 202,000 CL, valued at $21.6 million.
Brent Oil Position: The wallet also holds a small long position in Brent Oil with 20x leverage, alongside 10x short positions in HIMs and RIVN.
See More
Hims CEO's Pay Gap Sparks Attention Ahead of Vote
- Compensation Structure Analysis: Hims CEO Andrew Dudum's compensation of $22.96 million, down 7% from last year, remains 272 times the median employee pay, highlighting a significant pay gap that may impact the company's governance image.
- Performance Target Achievement: Hims met 94% of its revenue target and 98% of its adjusted EBITDA target last year, resulting in executives receiving 93.72% of their annual incentive bonuses, reflecting stable performance in the highly competitive GLP-1 weight-loss market.
- Stock Award Details: Dudum received 306,406 restricted stock units (RSUs) and performance-based stock options, with options convertible into 278,622 shares at minimum performance and up to 1.39 million shares at maximum performance, indicating the company's focus on long-term incentives.
- Intensifying Market Competition: Hims faces increasing competition in the GLP-1 market from Amazon and other digital platforms, recently expanding access to branded treatments from Novo Nordisk and Eli Lilly to enhance market share and address regulatory pressures.
See More
Hims Expands into Hormone Care and At-Home Testing Services
- Hormone Care Expansion: Hims recently launched Testosterone Rx+, a once-daily pill that combines Enclomiphene with zinc, vitamins B6, B12, and L-arginine, with 95% of users seeing increased testosterone levels within two months, highlighting the company's growth potential in hormone health.
- FDA Review Drives New Revenue: Bank of America Securities indicated that Hims' stock could rise due to upcoming FDA reviews of several peptide substances, which may open new revenue streams and allow the company to repurpose its existing GLP-1 infrastructure.
- Branded Drug Strategy: Hims' partnerships with Novo Nordisk and Eli Lilly signify a shift towards branded drugs, with expectations to exceed a run rate of over 100,000 Wegovy prescriptions per month, showcasing the company's competitive positioning in the market.
- Market Sentiment Shift: Despite Hims' shares rising over 1% on Monday, retail investor sentiment has shifted from 'bullish' to 'bearish', reflecting concerns about the company's future performance, with a 24% decline in stock price over the past year.
See More
Analysis of Investment Opportunities and Risks in Small-Cap Stocks
- Herbalife Performance Warning: With a market cap of $1.72 billion, Herbalife's organic sales have shown weakness over the past two years, and projected growth of only 4.3% over the next 12 months may force the company to make strategic adjustments or rely on M&A for faster growth.
- Jackson Financial Earnings Pressure: Jackson Financial, valued at $8.15 billion, has seen net premiums earned grow by just 1.9% annually over the last two years, while rising day-to-day expenses have led to a 32.8 percentage point drop in pre-tax profit margins, creating headwinds for future returns.
- Hims & Hers Health Optimistic Outlook: Hims & Hers Health, with a market cap of $6.19 billion, has averaged a 29.5% customer growth rate over the past two years, indicating strong capabilities in securing and expanding contracts, which could lead to significant sales growth.
- Market Volatility and Investment Strategy: Small-cap stocks like those in the Russell 2000 offer opportunities to uncover hidden gems, but their higher volatility and risk necessitate careful selection by investors, particularly during economic downturns.
See More
Hims Launches Testosterone Rx+ to Boost Hormone Therapy Offerings
- New Drug Launch: Hims has introduced Testosterone Rx+, a once-daily pill designed to help men naturally increase testosterone levels, marking a significant expansion in the company's hormone therapy offerings and potentially creating a new growth pillar.
- FDA Support: The rollout follows the FDA's encouragement for sponsors of approved testosterone replacement therapies to explore new indications for treating low libido, which could significantly boost market demand for testosterone therapies.
- Positive Customer Feedback: Company data indicates that 95% of customers experienced increases in testosterone levels, with 80% reaching optimal levels within 60 days, demonstrating the product's strong market appeal and effectiveness.
- Intensifying Market Competition: Amid tightening regulations on GLP-1 drugs, Hims' expansion into testosterone therapy is crucial for generating additional revenue streams, helping the company maintain competitiveness in the increasingly crowded weight-loss treatment market.
See More
FDA Proposes Exclusion of Weight Loss Drug Ingredients
- FDA Proposal: The U.S. Food and Drug Administration (FDA) has proposed to exclude Semaglutide and Tirzepatide from the 503B bulk list, limiting the compounding capabilities of outsourcing facilities, which may impact the market supply and accessibility of these drugs.
- Insufficient Clinical Need: The FDA stated that after reviewing available data, it found no clear clinical need to allow compounding of these drugs from raw ingredients, emphasizing patient safety and medical necessity, which could lead to restrictions on the use of related medications.
- Quality and Safety Concerns: The FDA has expressed concerns regarding the quality and safety of compounded weight-loss drugs, noting that these drugs are not reviewed by the FDA, which may pose risks such as improper storage, dosing errors, and counterfeit products, thereby affecting patient health.
- Market Reaction: Following the FDA proposal, shares of Eli Lilly and Novo Nordisk rose by 9% and 5%, respectively, indicating increased market confidence in the FDA-approved drugs from these companies, while Hims & Hers and Teladoc Health saw slight declines, reflecting market concerns over compounded medications.
See More
FalconX-Linked Address Adds 11.94 Million USDT to HyperLiquid, Boosting Crude Oil Long Position to 202,000 CL Tokens.
Investment in HyperLiquid: A wallet associated with Falcon X has deposited 11.94 million USDC into HyperLiquid, increasing its CL20x long position to 202,000 CL, valued at $21.6 million.
Brent Oil Position: The wallet also holds a small long position in Brent Oil with 20x leverage, alongside 10x short positions in HIMs and RIVN.
See More
Hims CEO's Pay Gap Sparks Attention Ahead of Vote
- Compensation Structure Analysis: Hims CEO Andrew Dudum's compensation of $22.96 million, down 7% from last year, remains 272 times the median employee pay, highlighting a significant pay gap that may impact the company's governance image.
- Performance Target Achievement: Hims met 94% of its revenue target and 98% of its adjusted EBITDA target last year, resulting in executives receiving 93.72% of their annual incentive bonuses, reflecting stable performance in the highly competitive GLP-1 weight-loss market.
- Stock Award Details: Dudum received 306,406 restricted stock units (RSUs) and performance-based stock options, with options convertible into 278,622 shares at minimum performance and up to 1.39 million shares at maximum performance, indicating the company's focus on long-term incentives.
- Intensifying Market Competition: Hims faces increasing competition in the GLP-1 market from Amazon and other digital platforms, recently expanding access to branded treatments from Novo Nordisk and Eli Lilly to enhance market share and address regulatory pressures.
See More
